BANGI: A collaboration was sealed to kickstart the development of human vaccines in Malaysia to pave the way toward health security.
Malaysian Vaccines and Pharmaceuticals (MPV) Healthcare, Pfizer Malaysia, and the National Institute of Biotechnology (NIBM) signed a Memorandum of Understanding (MOU) on Jan 30 at Malaysian Genome and Vaccine Institute (MGVI).
These three parties will work together to identify the gaps in the vaccine ecosystem, coordinate local vaccine companies and enhance research for infectious diseases.
The project aims to future-proof vaccine development that provides broad protection against pandemic threats or the emergence of any new infectious disease.
The Malaysian Government has given the mandate to NIBM-MGVI to explore the opportunities and coordinate the efforts among stakeholders involved in the vaccine ecosystem in November 2021.
“This initiative complements the direction set under the National Vaccine Development Roadmap (NVDR). Vaccine development is one of the subset roles under healthcare and wellness thrust in the National Biotechnology Policy 2.0 (NBP 2.0) that was launched last September,” said Chang Lih Kang, Minister of Science, Technology and Innovation during his speech.
